23351-91-9

Basic information

• Product Name: 5-BROMOISOPHTHALIC ACID
• Synonyms: 5-BROMOISOPHTHALIC ACID;5-BROMO-1,3-BENZENEDICARBOXYLIC ACID;5-BROMOISOPHTHALIC ACID 96%;5-Bromoisophthalic acid,96%;5-Bromobenzene-1,3-dicarboxylic acid;5-Bromo-1,3-benzenedicarboxyic acid;1,3-Benzenedicarboxylic acid, 5-bromo-;1,3-Benzenedicarbo
• CAS NO: 23351-91-9
• Molecular Formula: C₈H₅BrO₄
• Molecular Weight: 245.03
• EINECS: 245-602-6
• Mol File: 23351-91-9.mol

Chemical Properties

• Melting Point: 276-287 °C
• Boiling Point: 452.1 °C at 760 mmHg
• Flash Point: 227.2 °C
• Appearance: /
• Density: 1.875
• Vapor Pressure: 5.8E-09mmHg at 25°C
• Storage Temp.: Room temperature.
• PKA: 3.14±0.10(Predicted)
• Water Solubility: Insoluble in water.
• CAS DataBase Reference: 5-BROMOISOPHTHALIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMOISOPHTHALIC ACID(23351-91-9)
• EPA Substance Registry System: 5-BROMOISOPHTHALIC ACID(23351-91-9)

Safety Data

• Hazard Codes: Xi,T
• Statements: 36/37/38-25
• Safety Statements: 37/39-26-45-36/37/39
• RIDADR: 2811
• WGK Germany: 3
• TSCA: Yes
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 23351-91-9(Hazardous Substances Data)

Usage

Uses

Used in Coordination Polymer Synthesis:
5-BROMOISOPHTHALIC ACID is used as a reactant for the preparation of various coordination polymers, including manganese(II) bromoisophthalate bis(pyridyl)ethane, nickel(II) and cobalt(II) bromoisophthalate, copper bromoisophthalate bis(triazolyl)butane, and cesium isophthalate crown ether complexes. These coordination polymers have potential applications in areas such as gas storage, catalysis, and magnetism.
Used in Polymeric Complex Synthesis:
5-BROMOISOPHTHALIC ACID is also used as a reactant in the hydrothermal preparation of zinc and cadmium bromoisophthalate polymeric complexes with dipyridyl-type coligands. These polymeric complexes can be utilized in various applications, including advanced materials and chemical sensing.
General Description:
The product has been enhanced for energy efficiency, making it a more sustainable and environmentally friendly option for its intended applications.

InChI:InChI=1/C8H5BrO4/c9-6-2-4(7(10)11)1-5(3-6)8(12)13/h1-3H,(H,10,11)(H,12,13)/p-2

Upstream product

• 99-27-4 dimethyl 5-aminoisophthalate 
• 556-96-7 5-bromo-1,3-xylene 
• 121-91-5 isophthalic acid 
• 51760-21-5 dimethyl 5-bromoisophthalate 
• 1459-93-4 dimethyl Isophthalate 
• 618-83-7 5-Hydroxyisophthalic acid 

Downstream Products

• 51760-21-5 dimethyl 5-bromoisophthalate 
• 51760-22-6 5-bromo-1,3-dihydroxymethylbenzene 
• 57863-69-1 5-bromobenzene-1,3-dicarboxylic acid chloride 
• 127437-29-0 diethyl 5-bromo-1,3-benzenedicarboxylate 
• 120173-42-4 1,1‘-(5-bromo-1,3-phenylene)diethanone 
• 881302-73-4 benzene-1,3-dicarboxylic-5-boronic triacid 
• 357418-21-4 1-bromo-3,5-bis-((R)-1'-hydroxyethyl)benzene 
• 357418-23-6 1-bromo-3,5-bis-((S)-1'-phenoxyethyl)benzene 
• 357418-24-7 1-bromo-3,5-bis-((S)-1'-(2'',6''-dimethyl)-phenoxyethyl)benzene 
• 120173-41-3 5-bromobenzene-1,3-dicarbaldehyde 
• 263746-70-9 5-ethynyl-1,3-benzenedicarboxaldehyde 
• 263746-69-6 1,3-Bisformyl-5-trimethylsilylacetylenebenzene 
• 263746-71-0 m,m'-bisformylbenzene-4-ethynyl-benzaldehyde 
• 263746-74-3 C₂₀H₂₉BrN₄O₂ 

Relevant articles and documents

Synthesis and crystal structure of 5-bromoisophthalic acid

A new compound viz., 5-bromoisophthalic acid with the molecular formula C8H7BrO5 has been successfully synthesized by the reaction of isophthalic acid and N-bromosuccinimide (NBS). The compound has been characterized by X-ray single-crystal diffraction and shows a one-dimensional framework. The 3D supramolecular structure is formed via hydrogen bonding connection.

A NbO-type metal-organic framework exhibiting high deliverable capacity for methane storage

A copper-based NbO-type metal-organic framework ZJNU-50 constructed from a tetracarboxylate incorporating phenylethyne as a spacer exhibited an exceptionally high methane working capacity of 184 cm3 (STP) cm-3 for methane storage. The value is among the highest reported for MOF materials. This journal is

A new route for the preparation of 5-hydroxyisophthalic acid

A new, simple and practical, two-stage process for the preparation of 5-hydroxyisophthalic acid (5-HIPA) from isophthalic acid is described. In the first stage, isophthalic acid is brominated by bromine in oleum, in the presence of an iodine catalyst, to give crude 5-bromoisophthalic acid (5-BIPA). In the second stage the crude 5-BIPA is hydrolyzed with aqueous NaOH, in the presence of a copper catalyst, to give crude 5-HIPA, with a purity of ca. 98%. Both stages of the process were optimized. A single crystallization of the crude 5-HIPA from water gives the product in a purity of more than 99%. The overall yield of pure 5-HIPA is 65-70%.

COMPOSITIONS AND METHODS FOR SELECTIVE SEPARATION OF HYDROCARBON ISOMERS

The present invention relates to novel metal-organic frameworks (MOFs) comprising tetratopic linkers with small pore apertures. The present invention further relates to methods of utilizing the MOFs of the invention to separate hydrocarbons through adsorptive processes. The present invention further relates to the discovery that Ca(H2tcpb) metal-organic framework (MOF) is capable of separating hydrocarbon isomers from one another through absorptive processes. In one aspect, the invention provides a method of separating C5-C8 hydrocarbon isomers, such that straight chain, mono-branched, and/or multi-branched isomers are each separated from one another. In certain embodiments, this separation is achieved by taking advantage of the temperature dependent adsorptive properties of Ca(H2tcpb) MOF.

Anthraquinone compound and its preparation method and medical use (by machine translation)

The invention relates to a anthraquinone compound and its preparation method and medical use, cheap and easy to get to the isophthalic acid as the starting material, through the bromo, hydrolysis, esterification of the obtained intermediate with 2 - bromo - 5 - methoxy acyl chloride condensation, condensation product after hydrolysis, loop, debromination reduction to obtain the target product 1, 5 - dihydroxy - 3 - carboxyl - 9, 10 - anthraquinone. The reaction of the invention cheap, low cost, simple operation, high yield. Anti-tumor activity study results display, artificial synthesis of 1, 5 - dihydroxy - 3 - carboxyl - 9, 10 - anthraquinone has better anti-tumor activity. (by machine translation)

Monocrystalline iron metal organic frameworks

The invention relates to large single crystals of iron metal-organic framework materials comprising at least one iron metal ion, processes for preparing the same, methods for employing the same, and the use thereof. The invention also relates to monocrystalline and polycrystalline iron metal-organic frameworks.

Aluminum Metal Organic Framework Materials

The invention relates to monocrystalline single crystals of metal-organic framework materials comprising at least one aluminium metal ion, processes for preparing the same, methods for employing the same, and the use thereof. The invention also relates to monocrystalline aluminium metal-organic frameworks.

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract

Bromination of deactivated aromatics: A simple and efficient method

(Chemical Equation Presented) Highly deactivated aromatic compounds were smoothly monobrominated by treatment with N-bromosuccinimide (NBS) in concentrated H2SO4 medium affording the corresponding bromo derivatives in good yields. Mild reaction conditions and simple workup provides a practical and commercially viable route for the synthesis of bromo compounds of deactivated aromatics.

MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention is directed to macrocyclic tertiary amine compounds represented by general formula (I), which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.